Evit Labs and NovaCal Pharmaceuticals Sign Product Development Agreement

Evit Labs and NovaCal Pharmaceuticals Sign Product Development Agreement

McCLELLAN, Calif., April 25, 2002 - EVIT Labs, Inc. today announced it has signed an agreement with NovaCal Pharmaceuticals, LLC of Novato, California for the development of NovaCal's NVC-101 as an inhaled antimicrobial agent delivered to the lung by the Sonik LDI (liquid dispensing inhaler) for possible use against certain pulmonary infections and inhalation anthrax. EVIT and NovaCal intend to explore the impact of reducing the load of infectious agents within the lungs. Pulmonary infections are a major clinical concern and can be a weapon used by bio-terrorists.

The Sonik LDI is new technology platform for the sonic aerosolization of liquid pharmaceuticals, anti-bodies, proteins and peptides in a small, non-electrical, portable device.

NVC-101 is a proprietary noncytotoxic and antimicrobial solution designed and developed for the topical treatment of infected wounds

About the Companies

Founded in 2000, Evit Labs, Inc. is the leader in sonic delivery of high quality aerosol pharmaceutical, anti-bodies, proteins and peptides through its patented Sonik LDI (liquid dispensing inhaler). The company offers drug and biotech companies a patient friendly, economical, easy formulation, platform in which to deliver treatments to the lungs.

NovaCal Pharmaceuticals, LLC is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of patented therapeutic products for the control or elimination of infections. Currently, NovaCal is focused on clinical development and regulatory approval of NVC-101 as a unique topical noncytotoxic anti-microbial product.

NOTE: Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements and involve risks and uncertainties. They include our reliance on our collaborative partners and our ability to properly design, implement and complete clinical trial; meet regulatory requirements; demonstrate safety and efficacy of products; manage third-party contracts; and avoid infringement of third-party proprietary rights. Actual results may differ materially from those projected. These forward-looking statements represent our best judgment as of the date of the release. We disclaim any intent or obligation to update these forward-looking statements.